Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Journey Medical CorporationNASDAQ: DERM

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$189K, compared with -$2.1M a year earlier. Trailing-twelve-month EBITDA was -$1.44M.

Context

  • EBITDA amounted to 5.4% of revenue in FY2025, down 9.6 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of $4.51M (+235.5%) for the fiscal year ending Dec 2026, a step up from the +60.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$189K-124.4% QoQ
Last fiscal yearDec 2025
-$3.33M+60.4% YoY
LTMMar 2026
-$1.44M-0.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+91.0%+172.6%+81.6 pp
1 year+60.4%+235.5%+175.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(3.33M) USD
Year-over-year change
+60.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.6% is the 5th highest of 10, against a peer median of -19.8%.
  • EBITDA amounts to 2.2% of revenue for DERM, versus a peer median of 161.1%.
DERM Competitors
EBITDA for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGIOrganigram Global Inc.LTM Mar 2026CA$5.64M CAD-19.8%—2.1%
DERMJourney Medical CorporationLTM Mar 2026-$1.44M USD-0.6%—2.2%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026-$6.67M USD+35.5%—13.1%
MDWDMediWound Ltd.LTM Mar 2026-$14.84M USD+39.0%—102.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$52.72M USD+20.1%—161.1%
OSUROraSure Technologies, Inc.LTM Mar 2026-$63.7M USD-188.7%—56.4%
NYXHNyxoah S.A.LTM Mar 2026-€77.16M EUR-21.4%—472.8%
IVAInventiva S.A.FY2025-€128.15M EUR+23.0%—2858.6%
HSDTSolana CompanyLTM Mar 2026-$135.55M USD-1012.4%—1413.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$158.55M USD-341.7%—8932.3%
Peer median (excluding DERM) —-19.8%—161.1%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.13M73.67M79.18M56.13M61.86M
Cost of Revenue32.08M30.78M26.66M20.88M25.18M
Gross Profit31.05M42.89M52.52M35.26M36.68M
Gross Margin49.2%58.2%66.3%62.8%59.3%
Research & Development16.56M10.94M7.54M9.86M480K
Selling, General & Admin39.83M59.47M43.91M40.2M44.37M
Operating Expenses65.93M70.41M54.59M48.93M44.85M
Depreciation & Amortization2.56M4.37M3.86M3.52M4.35M
EBITDA(32.77M)(23.18M)1.92M(8.4M)(3.33M)
EBITDA Margin-51.9%-31.5%2.4%-15.0%-5.4%
Operating Income(34.88M)(27.52M)(2.07M)(13.68M)(8.17M)
Operating Margin-55.2%-37.4%-2.6%-24.4%-13.2%
Interest Income2K60K322K757K589K
Interest Expense7.03M2.02M1.7M2.7M3.7M
Other Income / Expenses(7.48M)(2.05M)(1.56M)(934K)(3.2M)
Income Before Tax(42.36M)(29.57M)(3.63M)(14.61M)(11.37M)
Pre-Tax Margin-67.1%-40.1%-4.6%-26.0%-18.4%
Income Tax Expense1.63M63K221K61K60K
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Net Margin-69.7%-40.2%-4.9%-26.1%-18.5%
EPS (Basic)(2.54)(1.69)(0.21)(0.72)(0.47)
EPS (Diluted)(2.54)(1.69)(0.21)(0.72)(0.47)
Weighted Avg Shares17.32M17.53M18.23M20.43M24.5M
Weighted Avg Shares (Diluted)17.32M17.53M18.23M20.43M24.5M

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.